Print ISSN: 2790-0207

Online ISSN: 2790-0215

Keywords : Serum ferritin

Evaluation of Serum Leptin and Ferritin Levels in Children with Major Beta-Thalassemia

Mutaz Sabah A; Khedhair Abbas K; Shaymaa Mohammed Salih

Kirkuk Journal of Medical Sciences, 2020, Volume 8, Issue 1, Pages 11-17

Background: Beta-thalassemia major regarded as one of the major health problems in endemic regions as the Mediterranean basin, part of North and West Africa and South East Asia. Endocrine complication occur in major beta thalassemia due to excessive iron accumulation in endocrine glands that result from frequent blood transfusion and chelation therapy that caused dysfunction in their hypothalamic-pituitary axis. The aim of the study is to determine the level of serum Leptin and to determine the relation of leptin level with ferritin level in children with beta-thalassemia major. Patients & Methods: A cross sectional study was carried out in Kirkuk City from January 2018 to March 2018 on 60 patients (30 female and 30 male) with beta thalassemia major and 30 age and sex matched healthy control (17 female and 13 male). Serum Leptin and ferritin levels were measured for both group by using commercial diagnostic kit. Results: The result of the present study showed that serum level of leptin hormone in children with beta thalassemia major less than control subjects but not statistically significant. While the differences in the serum ferritin level was significantly higher in children with beta –thalassemia major as compare with control subjects. Conclusion: Children with beta thalassemia major had a low level of leptin hormone than control subjects but not significant of same age and gender. Children with beta thalassemia major had a higher serum ferritin level than control subjects. Children with beta thalassemia major had a higher leptin level in female than male.

Deferoxamine vs. Deferasirox in the Treatment of Thalassemia Major with Iron Overload: Retrospective Study in Thalassemia Center, Kirkuk, Iraq

Jamal Qasim Weli; Mohammed Saleem Mohammed

Kirkuk Journal of Medical Sciences, 2013, Volume 1, Issue 2, Pages 30-36

Background: Iron overload is a major problem in patients with Thalassemia major. An effective and safe iron chelator protocol with high compliance rate plays an important role deciding the best treatment option in these patients. This study was done to assess the efficacy and safety of both Deferoxamine and Deferasirox in Thalassemia major patients in Kirkuk province, Iraq. Patients and methods: In this retrospective study we have included serum ferritin records of 280 Thalassemia major patients treated with two types of iron chelating therapy at Thalassemia center, Azadi teaching Hospital, Kirkuk province, Iraq. The study started since March 2012 till December 2012 and they were categorized in to two groups; First group Thalassemia major patients who had been treated with subcutaneous (SC infusion) Deferoxamine, while second group had been treated with oral Deferasirox (Exjade) with serum ferritin records of both base line and 9 month later had been compared. Most patients with relatively high serum ferritin had been treated with SC Deferoxamine. As a secondary end point, side effect profile had been analyzed in the two studied groups. Results: 173 Thalassemia major patients (mean age 11 year) treated with oral Deferasirox (Exjade) had mean decrease in their serum ferritin after 9 month was 840 ng/ml while the mean decrease in the 107 patients (mean age=17 year) treated with SC infusion Deferoxamine was (1527 ng/ml) with very significant difference between the two studied groups and (p-value = 0.0005). Abdominal cramp, nausea and vomiting, skin rash were more with oral Desferosix (Exjade) than SC Deferoxamine treated patients [52 (30%), 62 (35%), 13 (7%) versus 23 (21%), 11 (10%), 0 (0%) consecutively]. Renal impairment especially elevation of serum Creatinine to a degree requiring dose modification were found in 15 patients treated with oral Deferasirox (Exjade) while it has not been noticed in patients treated with Deferoxamine. Conclusion: In spite of less side effects and more compliance of Thalassemia Major Patients treated with Deferasirox than Deferoxamine; Deferoxamine still is more effective treatment modality than Deferasirox in decreasing serum ferritin level.